VM26 in malignant hematological diseases - A phase II study

Umberto Tirelli; Antonino Carbone; Giovanni Franchin; Enzo Galligioni; Andrea Veronesi; Mauro G. Trovo; Rachele Volpe; Salvatore Tumolo; Eligio Grigoletto

doi:10.1007/BF00254542

VM26 in malignant hematological diseases - A phase II study

Umberto Tirelli, Antonino Carbone, Giovanni Franchin, Enzo Galligioni, Andrea Veronesi, Mauro G. Trovo, Rachele Volpe, Salvatore Tumolo, Eligio Grigoletto

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

From August 1979 to April 1981, 33 consecutive patients with malignant hematological diseases, entered this phase II study. Sixteen patients had NHL, eight CLL, four Myeloma, three HD, one ALL, and one Polycythaemia vera. Two patients were unevaluable because of early death. The median age was 67 years. Eight patients were not pretreated with drugs. Two CR (5+, 20+ weeks) were obtained among NHL patients, whereas five PR were observed among two NHL, one CLL, one Myeloma, and one HD patients, respectively. Toxicity was almost exclusively hematologic and occurred in ten patients, in one of them causing severe myelosuppression. Moreover, severe asthenia, attributable to VM26, was encountered in three patients, in one requiring the suspension of the treatment.

Original language	English
Pages (from-to)	173-174
Number of pages	2
Journal	Cancer Chemotherapy and Pharmacology
Volume	7
Issue number	2-3
DOIs	https://doi.org/10.1007/BF00254542
Publication status	Published - 1982

ASJC Scopus subject areas

Cancer Research
Oncology
Pharmacology

Access to Document

10.1007/BF00254542

Cite this

@article{9d11826d126a4480ab2855f8309b3a44,

title = "VM26 in malignant hematological diseases - A phase II study",

abstract = "From August 1979 to April 1981, 33 consecutive patients with malignant hematological diseases, entered this phase II study. Sixteen patients had NHL, eight CLL, four Myeloma, three HD, one ALL, and one Polycythaemia vera. Two patients were unevaluable because of early death. The median age was 67 years. Eight patients were not pretreated with drugs. Two CR (5+, 20+ weeks) were obtained among NHL patients, whereas five PR were observed among two NHL, one CLL, one Myeloma, and one HD patients, respectively. Toxicity was almost exclusively hematologic and occurred in ten patients, in one of them causing severe myelosuppression. Moreover, severe asthenia, attributable to VM26, was encountered in three patients, in one requiring the suspension of the treatment.",

author = "Umberto Tirelli and Antonino Carbone and Giovanni Franchin and Enzo Galligioni and Andrea Veronesi and Trovo, {Mauro G.} and Rachele Volpe and Salvatore Tumolo and Eligio Grigoletto",

year = "1982",

doi = "10.1007/BF00254542",

language = "English",

volume = "7",

pages = "173--174",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2-3",

}

TY - JOUR

T1 - VM26 in malignant hematological diseases - A phase II study

AU - Tirelli, Umberto

AU - Carbone, Antonino

AU - Franchin, Giovanni

AU - Galligioni, Enzo

AU - Veronesi, Andrea

AU - Trovo, Mauro G.

AU - Volpe, Rachele

AU - Tumolo, Salvatore

AU - Grigoletto, Eligio

PY - 1982

Y1 - 1982

N2 - From August 1979 to April 1981, 33 consecutive patients with malignant hematological diseases, entered this phase II study. Sixteen patients had NHL, eight CLL, four Myeloma, three HD, one ALL, and one Polycythaemia vera. Two patients were unevaluable because of early death. The median age was 67 years. Eight patients were not pretreated with drugs. Two CR (5+, 20+ weeks) were obtained among NHL patients, whereas five PR were observed among two NHL, one CLL, one Myeloma, and one HD patients, respectively. Toxicity was almost exclusively hematologic and occurred in ten patients, in one of them causing severe myelosuppression. Moreover, severe asthenia, attributable to VM26, was encountered in three patients, in one requiring the suspension of the treatment.

AB - From August 1979 to April 1981, 33 consecutive patients with malignant hematological diseases, entered this phase II study. Sixteen patients had NHL, eight CLL, four Myeloma, three HD, one ALL, and one Polycythaemia vera. Two patients were unevaluable because of early death. The median age was 67 years. Eight patients were not pretreated with drugs. Two CR (5+, 20+ weeks) were obtained among NHL patients, whereas five PR were observed among two NHL, one CLL, one Myeloma, and one HD patients, respectively. Toxicity was almost exclusively hematologic and occurred in ten patients, in one of them causing severe myelosuppression. Moreover, severe asthenia, attributable to VM26, was encountered in three patients, in one requiring the suspension of the treatment.

UR - http://www.scopus.com/inward/record.url?scp=0020072846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020072846&partnerID=8YFLogxK

U2 - 10.1007/BF00254542

DO - 10.1007/BF00254542

M3 - Article

C2 - 6952964

AN - SCOPUS:0020072846

SN - 0344-5704

VL - 7

SP - 173

EP - 174

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2-3

ER -

VM26 in malignant hematological diseases - A phase II study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this